Meeting
2015 Gastrointestinal Cancers Symposium
Phase 3 randomized, double-blind, controlled study of cabozantinib (XL184) versus placebo in subjects with hepatocellular carcinoma who have received prior sorafenib (CELESTIAL; NCT01908426).
Authors
Ghassan K. Abou-Alfa
Memorial Sloan Kettering Cancer Center, New York, NY
Ghassan K. Abou-Alfa , Ann-Lii Cheng , Tim Meyer , Anthony B. El-Khoueiry , Masafumi Ikeda , Hoo Geun Chun , Junji Furuse , Jennifer J. Knox , Takuji Okusaka , Jerry Ping , Anne E. Borgman-Hagey , Robin Kate Kelley
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT01908426
Citation
J Clin Oncol 33, 2015 (suppl 3; abstr TPS496)
DOI
10.1200/jco.2015.33.3_suppl.tps496
Abstract #
TPS496
Poster Bd #
F11
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Phase 3 randomized, double-blind, controlled study of cabozantinib (XL184) versus placebo in subjects with hepatocellular carcinoma who have received prior sorafenib (CELESTIAL; NCT01908426).
First Author: Ghassan K. Abou-Alfa
Poster
2018 ASCO Annual Meeting
Outcomes in patients (pts) who had received sorafenib (S) as the only prior systemic therapy in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC).
First Author: Robin Kate Kelley
Poster
2019 ASCO Annual Meeting
Phase 3 (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) versus sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy.
First Author: Robin Kate Kelley
Poster
2019 Gastrointestinal Cancers Symposium
Alpha fetoprotein (AFP) response and efficacy outcomes in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC).
First Author: Robin Kate Kelley